恩替卡韦治疗失代偿期肝硬化疗效观察

目的观察恩替卡韦治疗失替偿期乙型肝炎肝硬化的疗效。方法对2006年3月至2007年6月18例来我院就诊乙型肝炎肝硬化失代偿期患者给予口服恩替卡韦治疗剂量0．5mg／次,1次／d,基本疗程1年。观察HBV-DNA定量,肝纤维化指标（HA、LN、POⅢ、Ⅳ—C）,肝功能指标（ALT、AST、TBIL）变化情况。结果所有患者临床症状明显改善,肝功能指标、HBV—DNA定量、肝纤四项指标改善有非常显著差异（P〈0．01）。结论恩替卡韦治疗乙型肝炎失代偿期肝硬化可有效抑制病毒复制,改善肝功能,阻止肝纤维化进展,防止病情恶化。

Clinical observation of Entecavir in the treatment of decompensated cirrhosis

Objective：To observe the curative effect of Entecavir on decompensated Hepatitis B cirrhosis. Methods：18 patients with decompensated Hepatitis B cirrhosis from march 2006 to June 2007 in our hospital were treated with Entecavir at a dosage of 0.5mg per day. The basic course of treatment was one year. The levels of HBV-DNA, serum liver fibrosis indexes （HA,LN,PC Ⅲ,Ⅳ-C） and liver function indexes（ALT,AST,TBIL） were measured at 6 months interval.Results：The clinical symptoms were markedly improved after trcatment.Conclusion：Entecavir can effectively inhibit the copying of HBV,improve liver function,slow down the development of liver fibrosis and prevent the deterioration of decompensated cirrhosis.